Harrow (HROW) Stock Overview
An eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for HROW from our risk checks.
HROW Community Fair Values
Create NarrativeSee what 23 others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Harrow, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$36.35 |
| 52 Week High | US$54.85 |
| 52 Week Low | US$20.85 |
| Beta | 0.098 |
| 1 Month Change | -29.49% |
| 3 Month Change | -27.53% |
| 1 Year Change | 31.46% |
| 3 Year Change | 74.80% |
| 5 Year Change | 438.52% |
| Change since IPO | 320.30% |
Recent News & Updates
Recent updates
Harrow Emerging As Dominant Operator In U.S. Ophthalmic Market
Mar 17Harrow, Inc. (NASDAQ:HROW) Looks Just Right With A 27% Price Jump
Oct 03
VEVYE And TRIESENCE Programs Will Expand Prescription Access
Harrow is focusing on boosting sales and profitability through patient affordability programs, strategic supply chain improvements, and next-gen product developments.Harrow: When Cheaper Doesn't Mean Attractive (Rating Upgrade)
Mar 29Harrow: A Name I Am Accumulating
Mar 19Smallcap Eyecare Pharma Company Harrow Health Has Two Major Catalysts For 2025
Mar 01Shareholders Should Be Pleased With Harrow, Inc.'s (NASDAQ:HROW) Price
Feb 17Harrow: The Triesence Relaunch
Dec 14Harrow: Spotlight On IHEEZO
Nov 16Harrow's Focus - Reviving Old Drugs In A Crowded Market
Oct 02Harrow: 3 Business Models, One Mission
Sep 10Borrowing Cash To Burn It: The Curious Case Of Harrow
Aug 21Harrow: The Bull Thesis Is On Track, But Short-Term Challenges Loom
May 02Harrow's Drug Iheezo Is Off To A Great Start
Feb 19Harrow: Temporary Disruption In Stock Price Creates Excellent Opportunity
Jan 30Shareholder Returns
| HROW | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 5.4% | 0.7% | -0.1% |
| 1Y | 31.5% | 23.1% | 15.9% |
Return vs Industry: HROW exceeded the US Pharmaceuticals industry which returned 19.3% over the past year.
Return vs Market: HROW exceeded the US Market which returned 13.3% over the past year.
Price Volatility
| HROW volatility | |
|---|---|
| HROW Average Weekly Movement | 10.8% |
| Pharmaceuticals Industry Average Movement | 9.4% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in US Market | 15.9% |
| 10% least volatile stocks in US Market | 3.3% |
Stable Share Price: HROW has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: HROW's weekly volatility (11%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 373 | Mark Baum | www.harrow.com |
Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products in the United States. It operates through Branded and ImprimisRx segments. The company offers ImprimisRx, an ophthalmology-focused compounded medications.
Harrow, Inc. Fundamentals Summary
| HROW fundamental statistics | |
|---|---|
| Market cap | US$1.31b |
| Earnings (TTM) | -US$5.14m |
| Revenue (TTM) | US$272.30m |
Is HROW overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HROW income statement (TTM) | |
|---|---|
| Revenue | US$272.30m |
| Cost of Revenue | US$67.93m |
| Gross Profit | US$204.37m |
| Other Expenses | US$209.51m |
| Earnings | -US$5.14m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.14 |
| Gross Margin | 75.05% |
| Net Profit Margin | -1.89% |
| Debt/Equity Ratio | 466.8% |
How did HROW perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/03/25 17:43 |
| End of Day Share Price | 2026/03/25 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Harrow, Inc. is covered by 10 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Mayank Mamtani | B. Riley Securities, Inc. |
| Thomas Shrader | BTIG |
| Steven Seedhouse | Cantor Fitzgerald & Co. |